Sulfonamide Drug Allergy

被引:39
作者
Dorn, Joshua M. [1 ]
Alpern, Mollie [1 ]
McNulty, Caitlin [1 ]
Volcheck, Gerald W. [1 ]
机构
[1] Mayo Clin, Div Allerg Dis, 200 First St SW, Rochester, MN 55905 USA
关键词
Sulfonamide; Hypersensitivity; Drug allergy; Cross-reactivity; Cross-sensitivity; PNEUMOCYSTIS-CARINII-PNEUMONIA; TOXIC EPIDERMAL NECROLYSIS; HIV-INFECTED PATIENTS; STEVENS-JOHNSON SYNDROME; CROSS-REACTIVITY; TRIMETHOPRIM-SULFAMETHOXAZOLE; HYPERSENSITIVITY REACTIONS; METASTATIC MELANOMA; ANAPHYLACTIC SHOCK; ADVERSE EVENTS;
D O I
10.1007/s11882-018-0791-9
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
We sought to review past and current literature on sulfonamide drug allergy and distill it in a practical manner to assist the clinician, specifically focusing on cross-reactivity and desensitization. There do not appear to be consistent genetic markers to reliably predict features of or the presence hypersensitivity reactions. Recent evidence continues to alleviate early concerns cross-reactivity between sulfonamide antibiotics and non-antibiotics. Sulfonamide drug allergy is frequently encountered by the practicing clinician. For sulfonamide antibiotics, delayed rash is the most common clinical manifestation. There is no current evidence to support avoidance of all non-antibiotic sulfonamides in those with a reported allergy to sulfonamide antibiotics, although certain scenarios require caution. Available evidence supports the cautious reintroduction of sulfonamide antibiotics via desensitization, which is usually well tolerated and should be considered in those with strong indications for trimethoprim-sulfamethoxazole and a reported sulfonamide allergy.
引用
收藏
页数:10
相关论文
共 106 条
[1]   Topical acne drugs review of clinical properties, systemic exposure, and safety [J].
Akhavan, A ;
Bershad, S .
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2003, 4 (07) :473-492
[2]   RAPID ORAL DESENSITIZATION TO FUROSEMIDE [J].
Alim, Naureen ;
Patel, Julie Y. .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2009, 103 (06) :538-538
[3]   Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks [J].
Anforth, R. ;
Carlos, G. ;
Clements, A. ;
Kefford, R. ;
Fernandez-Penas, P. .
BRITISH JOURNAL OF DERMATOLOGY, 2015, 172 (01) :239-243
[4]  
Anliker MD, 2003, J INVEST ALLERG CLIN, V13, P66
[5]  
[Anonymous], 1973, LANCET, V2, P950
[6]  
Author S, 1988, SOURCE J INFECT DIS, V158, P474
[7]   Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds [J].
Bellon, T. ;
Lerma, V. ;
Gonzalez-Valle, O. ;
Gonzalez Herrada, C. ;
de Abajo, F. J. .
BRITISH JOURNAL OF DERMATOLOGY, 2016, 174 (03) :621-624
[8]   Safety of dapsone as Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with allergy to trimethoprim/sulfamethoxazole [J].
Beumont, MG ;
Graziani, A ;
Ubel, PA ;
MacGregor, RR .
AMERICAN JOURNAL OF MEDICINE, 1996, 100 (06) :611-616
[9]  
BIGBY M, 1986, JAMA-J AM MED ASSOC, V256, P3358
[10]  
Bigby M, DRUG INDUCED CUTANEO